Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 189Gynecologic 10Gastrointestinal 9Genitourinary 7Thoracic 6Head & Neck 5CNS 3Sarcoma 2Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Dermatologic 2Classical hematology 2Myeloid 1

Conditions

Breast Neoplasms 2Venous Thromboembolism 1Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Cardiovascular Diseases 1Blast Crisis 1Anemia 1

Interventions

Epoetin Alfa 6olaparib 5pegfilgrastim 3Filgrastim 3Carboplatin 3pembrolizumab 2pegylated granulocyte colony-stimulating factor 2palbociclib 2abemaciclib 2Tretinoin 2venetoclax 1trametinib 1talazoparib 1stinging nettle lectin 1ruxolitinib 1ribociclib 1regorafenib 1ponatinib 1pertuzumab 1peppermint oil 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1fludarabine phosphate 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × palbociclib × Classical hematology × Clear all
NCT07008508 2025-06-06

BRAVE-Cyclin

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Active not recruiting
300 enrolled
BreastClassical hematology

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡